Understanding how a key antibody targets cancer cells
Important molecular insights for designing improved cancer therapies.
By Erin MatthewsDoctor
Immunotherapy can be used as a precise intervention in cancer treatments. Jean-Philippe Julien is a Canada Research Chair in Structural Immunology, a Senior Scientist in the Molecular Medicine Program at The Hospital for Sick Children (SickKids), and an Associate Professor in the Departments of Biochemistry and Immunology at the University of Toronto. Along with colleagues from the U.S., Spain and Canada, he used the Canadian Light Source at the University of Saskatchewan to study how a candidate antibody therapeutic interacts with a surface receptor on cancer cells, which provides important molecular insights for designing improved cancer therapies. He mentioned how the synchrotron is “incredibly important for researchers like myself” and how “we cannot do the research that we do without it.” The team used the CMCF beamline at the CLS and their findings were published in the Journal of Biological Chemistry.
-
Ereño-Orbea, June, Xianglei Liu, Taylor Sicard, Iga Kucharska, Wei Li, Dorota Borovsky, Hong Cui, Yang Feng, Dimiter S. Dimitrov, and Jean-Philippe Julien. "Structural details of monoclonal antibody m971 recognition of the membrane-proximal domain of CD22." Journal of Biological Chemistry 297, no. 2 (2021). DOI: 10.1016/j.jbc.2021.100966.
Media Relations:
Victoria Schramm
Communications Coordinator
Canadian Light Source
306-657-3516
victoria.schramm@lightsource.ca